NHS Weight Loss Injections - Ozempic, Wegovy and Mounjaro For Obesity - The Ultimate Guide

Weight loss injections like Ozempic, Wegovy, and Mounjaro are gaining popularity in the UK due to their convenience, accessibility and effectiveness in aiding weight loss.

As a new NHS hot topic, medical school applicants must understand these weight loss treatments and their role in combating the UK Obesity Crisis.

These drugs are best understood as one response to a much bigger problem. For the full picture, read our guide to the obesity crisis in the UK and how prevention measures such as the sugar tax fit alongside medical treatment.

This article provides insights for UK medical school interview preparation and offers clear information for those interested in the NHS approach to weight loss management which will be useful during ethical discussions at your medicine interview.

Weight Loss Injections Summary - What You Need To Know

1. Wegovy, Ozempic, and Mounjaro are weight loss injections designed to help manage obesity by mimicking hormones that suppress appetite.
2. Wegovy is available on the NHS for patients with a high BMI and related health conditions, following strict eligibility criteria.
3. Weight loss injections are effective for weight loss but raise ethical concerns about access, long-term safety, and potential dependency.
4. Understanding the role of weight loss jabs in obesity management is essential for medical school interviews, as they are a key NHS hot topic. 👉🏻 Read more: Everything You Need To Know About Your UK Medical School Interview

What is Ozempic and can you get it on the NHS?

Ozempic is a brand name for semaglutide, a prescription medication primarily used to treat type 2 diabetes.

It works at a hormonal receptor, known as the GLP-1 receptor, which signals our body and brain to feel full, or satiated.

It also triggers insulin release from the pancreas, which allows glucose to enter the body’s cells, reducing blood glucose levels.

These mechanisms aid weight loss.

Though Ozempic was originally intended for diabetes management, Ozempic has gained attention for its effectiveness in supporting weight loss, with many celebrities using this medication.

👉🏻 Read more: The UK Obesity Crisis

Can you get Ozempic on the NHS for weight loss?

Semaglutide branded under Ozempic is not licensed for use as a weight loss drug in the UK.

It is only licensed for use in diabetic patients.

👉🏻 Read more: Current Hot Topics in Medicine

Weight Loss Medication: What Is Wegovy?

Wegovy is a brand name for semaglutide, which is specifically approved for weight management in the UK.

It is a once-weekly weight loss injection, which when combined with a healthy diet and exercise can increase weight loss.

It can be used for a maximum of 2 years.

Wegovy was launched for weight loss in the UK in September 2023 and is available via prescription for those meeting specific criteria set by the National Insitute for Health and Care Excellence (NICE).

👉🏻 Read about another NHS Hot Topic: The NHS Pharmacy First Initiative

Is Wegovy Available In The UK?

Wegovy is available in the UK.

It was launched in the UK in September 2023 and is now available on the NHS for patients who meet the eligibility criteria set by NICE.

Wegovy is licensed for adults struggling with obesity and weight-related health conditions.

To be prescribed Wegovy on the NHS, patients must meet the following criteria:

• Body Mass Index (BMI) of 35 or above, with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or cardiovascular disease.
• BMI of 30 or above (in certain cases), if referred to specialist weight management services.
• Individuals from some ethnic minority backgrounds may qualify with a lower BMI due to differing health risks associated with weight.

It must be prescribed alongside a reduced-calorie diet, exercise, and behavioural support.

👉🏻 Read about another NHS Hot Topic: Max and Keira’s Law

Weight Loss Injection: How Does Wegovy Work?

Like Ozempic, Wegovy works by mimicking the action of the hormone glucagon-like peptide-1 (GLP-1), which helps regulate appetite and increases feelings of fullness.

Reducing hunger and slowing down stomach emptying help patients consume fewer calories and support weight loss.

👉🏻 Read more: BMA Junior Doctor Strikes in the UK

What is Mounjaro (tirzepatide)?

Mounjaro is the brand name for tirzepatide, a prescription primarily used to manage type 2 diabetes, and more recently, to aid weight loss in obesity.

Like other weight loss injections, it has also shown potential for significant weight loss when used alongside diet and exercise.

👉🏻 Read more: 280 Medical School MMI Interview Questions

Is Mounjaro available on the NHS in the UK?

Mounjaro is currently licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for weight loss in adults with a BMI of 30 or more, or for those with a BMI of 27+ who have weight-related health problems.

Mounjaro is now recommended by NICE (TA1026) for weight management as well as for type 2 diabetes, and the NHS began prescribing it for obesity through GPs from 23 June 2025.

It can be bought privately for obesity and is now also available on the NHS, but only to prioritised patients during a phased rollout, so most people who are eligible will wait their turn.

NICE recommended Mounjaro for obesity in TA1026 and the NHS rollout began in primary care on 23 June 2025. Because demand is huge, access is being phased in over up to 12 years, with around 220,000 patients expected to be treated in the first three years and up to 3.4 million over 12 years. The first eligible cohort is broadly those with a BMI of 40 or more and at least four weight-related conditions, with a lower BMI threshold for several ethnic groups. It still requires a prescription and wraparound diet, activity and behavioural support, and cannot be bought over the counter.

👉🏻 Read more: The NHS GP Shortage

Weight Loss Jab: How Does Mounjaro Work?

Like Ozempic and Wegovy, Mounjaro works by mimicking the effects of GLP-1, a hormone that suppresses appetite and slows digestion.

However, Mounjaro also targets a second hormone, GIP, which helps to regulate energy balance and further enhances weight loss.

This dual action makes Mounjaro more effective in promoting weight loss than drugs targeting GLP-1 alone.

👉🏻 Read more: NHS Postcode Lottery

NHS Weight Loss Injections: Ozempic Vs Mounjaro Comparison

Both Wegovy and Mounjaro are popular weight loss injections, but there are key differences between the two that are important to understand:

• Active Ingredients: Wegovy contains semaglutide, a GLP-1 agonist, while Mounjaro contains tirzepatide, which targets both GLP-1 and GIP, giving it a dual mechanism of action.
• Effectiveness: Studies suggest that Mounjaro may be more effective for weight loss due to its dual hormonal action, whereas Wegovy is still highly effective but works solely on GLP-1 receptors.
• Licensing: both are now licensed and funded for weight loss on the NHS. Wegovy is offered through specialist (Tier 3/4) weight-management services, while Mounjaro began a phased NHS rollout through GPs from 23 June 2025 (NICE TA1026).
• Availability: Wegovy is available through specialist (Tier 3/4) weight-management services for those meeting NICE criteria, and from April 2026 a separate NICE recommendation also allows some people with existing cardiovascular disease and a BMI of 27 or above to access it. Mounjaro is now available on the NHS through GPs under a phased rollout that began on 23 June 2025, starting with the highest-risk patients.

Both drugs offer significant weight-loss potential, and Mounjaro's dual action may make it more powerful for some individuals. Both are now funded by the NHS, but access is rationed: Wegovy runs through specialist services and Mounjaro is being phased in slowly through GPs to protect NHS capacity.

👉🏻 Read more: How To Answer Ethical Questions at Your Medicine Interview

Who is eligible for weight loss injections on the NHS?

Weight loss drugs are only available on the NHS for patients who meet specific criteria relating to weight and health risk factors.

These drugs are prescribed through specialist weight management services and are not available for general weight loss purposes.

To qualify for weight loss drugs on the NHS, you must meet the following criteria:

• Have a Body Mass Index (BMI) of 35 or more and at least one weight-related health condition, such as hypertension or cardiovascular disease.
• In exceptional cases, individuals with a BMI between 30 and 34.9 and a weight-related comorbidity can also qualify.
• People from certain ethnic backgrounds may qualify at a lower BMI threshold due to increased health risks associated with obesity.

Weight loss drugs are prescribed alongside a programme of diet, exercise, and behavioural support, and are generally only prescribed for up to two years.

👉🏻 Read more: NHS Winter Pressures & Bed Shortages

Wegovy and Moujaro Effectiveness: How Effective Are Weight Loss Injections?

Both Wegovy and Mounjaro have been shown to be effective in aiding weight loss when used alongside a healthy diet and exercise plan.

Clinical trials have shown that Wegovy users can achieve up to a 15% reduction in body weight after a year of treatment.

Mounjaro has demonstrated even higher weight loss potential in some studies, with users experiencing up to 20% body weight reduction in clinical trials.

👉🏻 Read more: NHS Backlog and Waiting Times

Can you buy weight loss injections privately, and what do they cost?

Why buying weight loss jabs online can be dangerous

The huge demand for these drugs has created a thriving market for unsafe, unregulated and even counterfeit products. The MHRA has issued repeated warnings about fake Mounjaro and Wegovy pens sold through social media, beauty salons and unverified websites, and in 2025 dismantled the UK's first illegal weight-loss drug factory.

Genuine UK pharmacies never sell prescription weight-loss injections through TikTok, Instagram or WhatsApp, and never ask for payment by bank transfer or cryptocurrency. Regulators have also criticised questionnaire-only online services that hand out prescriptions without a proper clinical assessment or follow-up.

In my GP clinics I always remind patients that a price that looks too good to be true usually is. This is a strong interview point: it links patient safety, the doctor's role in safe prescribing, and the risks created when NHS access is limited and demand spills into a poorly regulated private market.

Weight-loss drugs such as Wegovy and Mounjaro are available privately in the UK.

It's important to note that these medications should only be purchased from regulated sources to ensure safety and proper medical guidance. Buying from unregulated sellers can pose serious health risks.

👉🏻 Read more: 7 Day NHS

Weight Loss Injections: Side Effects Of Wegovy & Mounjaro

Weight loss injections like Wegovy and Mounjaro can cause several side effects, which vary in severity.

Common side effects include:

• Nausea and vomiting
• Bloating and indigestion
• Constipation or diarrhoea
• Fatigue
• Mild hair loss

For many, these side effects are manageable and often improve with time.

However, in rare cases, more serious side effects such as gallbladder issues, pancreatitis, or kidney problems may occur.

👉🏻 Read more: The NHS Long-Term Workforce Plan

Weight Loss Injections: What Happens When You Stop Taking Weight Loss Drugs?

When weight loss injections like Wegovy or Mounjaro are stopped, there is a risk that patients may regain the weight they lost.

Once the treatment is discontinued, normal hunger signals and cravings can return, and some individuals might find it challenging to maintain reduced calorie intake.

To help prevent weight regain, it is essential to maintain the healthy eating habits, exercise routines, and lifestyle changes developed while on the treatment.

👉🏻 Read more: NHS Mental Health Crisis

Weight Loss Drugs: Ethical Considerations of Ozempic, Wegovy and Mounjaro

There are a number of ethical considerations associated with the use of weight loss drugs. You should be able to discuss these in your UK medical school interview:

1) Access and Equality:

These treatments are often only accessible through specialist weight management services, creating a disparity between those who can access the NHS and those who can afford private prescriptions.

Not everyone who could benefit from these treatments may have access, especially if they can't afford private prescriptions.

Arguably this could encourage people to try and purchase weight loss medications online through unregulated suppliers, putting them at risk.

This raises concerns about equality and justice in healthcare, as not everyone who could benefit from these medications may have access to them, particularly patients from lower-income backgrounds.

The availability of private options may further widen health disparities, especially among ethnic minorities, who may already face increased health risks associated with obesity but are less likely to have access to private care.

Addressing these inequalities is crucial to ensuring that advances in weight loss treatments do not exacerbate existing social and economic divides in healthcare.

2) Medicalisation of Obesity:

There are concerns that relying on weight loss drugs could lead to the over-medicalisation of obesity, shifting the focus away from tackling the root causes like unhealthy diets, lifestyle, and socioeconomic factors.

Strong applicants link this to upstream prevention. Critics argue that money spent on injections could instead support population-level measures such as the sugar tax and wider food policy, which aim to prevent obesity rather than treat it once established.

It is arguable that lifestyle changes should still be prioritised over viewing medications as a “quick fix.”

3) Long-Term Safety and Dependency:

While effective, there are concerns about the long-term safety of these drugs and the risk of developing a dependency.

It is known that patients may regain weight after stopping the medication, particularly if lifestyle changes are not upheld.

This raises questions about whether these drugs could create a reliance on lifelong treatment.

👉🏻 Read more: NHS Core Values

Weight Loss Medications - Potential Medicine Interview Questions

How to structure an answer on weight loss injections

When I interview applicants, I am not looking for someone who simply approves or condemns these drugs. I want a balanced answer that shows you can weigh competing principles. A reliable structure is to anchor your reasoning in the four pillars of medical ethics.

• Beneficence: GLP-1 drugs produce real, clinically meaningful weight loss (around 15% with Wegovy and up to roughly 20% with Mounjaro in trials) and can reduce the risk of conditions like type 2 diabetes and heart disease.
• Non-maleficence: they carry side effects, the long-term safety picture is still developing, and weight is often regained when treatment stops, raising questions about lifelong reliance.
• Justice: access is rationed. With up to 3.4 million people eligible over 12 years, the NHS cannot treat everyone at once, and those who can pay privately get faster access, which risks widening health inequalities.
• Autonomy: patients can choose to seek treatment, but genuine choice depends on honest information about benefits, risks and the importance of lifestyle change alongside the drug.

Finish by acknowledging the bigger picture: medication is one tool, but tackling obesity also needs prevention, food policy and addressing the social causes of poor diet. That shows the maturity interviewers reward.

1. What are the ethical considerations of offering weight loss injections such as Wegovy on the NHS?
2. How do weight loss injections fit into the wider strategy to combat the UK's obesity crisis?
3. Do you think the NHS should prioritise medication like Wegovy over lifestyle changes for obesity management? Why or why not?
4. Do you think weight loss injections like Mounjaro and Wegovy will help address the root causes of obesity, or do they only treat the symptoms?
5. Weight loss injections have been shown to cause weight regain once stopped. How should this be managed in clinical practice?
6. What do you know about weight loss injections?
7. Do you agree that weight loss injections should be available to purchase privately?